Global Inactivated Vaccine Market

Inactivated Vaccine Comprehensive Study by Type (By End User, Pediatrics, Adults, By Disease Indication, Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), Application (Hospital, Medical Center) Players and Region - Europe Market Outlook to 2030

Inactivated Vaccine Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Inactivated Vaccine is referred to as the vaccines, which are produced by killing or inactivated bacteria or viruses by chemical treatment or heat. This group includes, for example, the inactivated poliovirus (IPV) vaccine, rabies vaccine, pertussis vaccine, or hepatitis A virus vaccine. The market of the inactivated vaccines is increasing as there are various technical advancement in admiration, also there is rising in the infectious diseases and allergies, but there are some challenges which are hindering the market like it takes a longer time for the vaccine production thus it is lowering the market

Highlights from Inactivated Vaccine Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The key Players profiled in the report are Astellas Pharma (Japan), CSL Limited (Australia), Emergent BioSolutions (United States), GlaxoSmithKline (United Kingdom), Johnson & Johnson (United States), MedImmune (United States), Merck & Co (United States) and Pfizer (United States). Additionally, other players that are part of this comprehensive study are Sanofi Pasteur (France) and Serum Institute of India Pvt (India).

Geographic Breakdown and Segment Analysis
The Europe Inactivated Vaccine market presents a comprehensive analysis of the Inactivated Vaccine market by product type (By End User, Pediatrics, Adults, By Disease Indication, Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio and MMR), by end-user/application (Hospital and Medical Center), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Europe Inactivated Vaccine industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Inactivated Vaccine market

Analyst at AMA have segmented the market study of Europe Inactivated Vaccine market by Type, Application and Region.

Influencing Trend:
Expansion of customised vaccines and Implementation of Artificial Intelligence (AI) and Big Data Analytics to improve surveillance capacity

Market Growth Drivers:
Technical advancements in admiration to the expansion of inactivated vaccines, Rising infectious diseases and allergies and Improving healthcare infrastructure

Challenges:
Longer timeline for vaccine production and High cost associated with development of vaccine

Restraints:
Imbalance in the curing of disease and Safety and efficacy related issues

Opportunities:
Substantial investments made in the field of research and development of vaccines and technologies is improving the market growth

Market Developments Activities:
In August , 2021, AVAT is pleased to announce the shipment of 108,000 of the Johnson & Johnson single-shot vaccines to Mauritius on the 7th of August. This is part of a total of 6.4m vaccine doses to be shipped to African Union Member States in August 2021. The Member States who have ordered vaccines through AVAT will continue to receive shipments for the next following months.
Astellas Launches XOSPATA in the U.S. for the treatment of adult patients with relapsed/refractory acute Myeloid Leukemia (AML) with a FLT3 Mutation





Key Target Audience
Inactivated Vaccine providers, laboratories, Channel partners, Industry association, Downstream vendors, Government and investment communities, Research organisation and associations and End user

Report Objectives / Segmentation Covered

By Type
  • By End User
  • Pediatrics
  • Adults
  • By Disease Indication
  • Pneumococcal
  • Influenza
  • HPV
  • Hepatitis
  • Rotavirus
  • DTP
  • Polio
  • MMR
By Application
  • Hospital
  • Medical Center
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technical advancements in admiration to the expansion of inactivated vaccines
      • 3.2.2. Rising infectious diseases and allergies
      • 3.2.3. Improving healthcare infrastructure
    • 3.3. Market Challenges
      • 3.3.1. Longer timeline for vaccine production
      • 3.3.2. High cost associated with development of vaccine
    • 3.4. Market Trends
      • 3.4.1. Expansion of customised vaccines
      • 3.4.2. Implementation of Artificial Intelligence (AI) and Big Data Analytics to improve surveillance capacity
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Europe Inactivated Vaccine, by Type, Application and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Europe Inactivated Vaccine (Value)
      • 5.2.1. Europe Inactivated Vaccine by: Type (Value)
        • 5.2.1.1. By End User
        • 5.2.1.2. Pediatrics
        • 5.2.1.3. Adults
        • 5.2.1.4. By Disease Indication
        • 5.2.1.5. Pneumococcal
        • 5.2.1.6. Influenza
        • 5.2.1.7. HPV
        • 5.2.1.8. Hepatitis
        • 5.2.1.9. Rotavirus
        • 5.2.1.10. DTP
        • 5.2.1.11. Polio
        • 5.2.1.12. MMR
      • 5.2.2. Europe Inactivated Vaccine by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Medical Center
      • 5.2.3. Europe Inactivated Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Europe Inactivated Vaccine (Volume)
      • 5.3.1. Europe Inactivated Vaccine by: Type (Volume)
        • 5.3.1.1. By End User
        • 5.3.1.2. Pediatrics
        • 5.3.1.3. Adults
        • 5.3.1.4. By Disease Indication
        • 5.3.1.5. Pneumococcal
        • 5.3.1.6. Influenza
        • 5.3.1.7. HPV
        • 5.3.1.8. Hepatitis
        • 5.3.1.9. Rotavirus
        • 5.3.1.10. DTP
        • 5.3.1.11. Polio
        • 5.3.1.12. MMR
      • 5.3.2. Europe Inactivated Vaccine by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Medical Center
      • 5.3.3. Europe Inactivated Vaccine Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Europe Inactivated Vaccine (Price)
      • 5.4.1. Europe Inactivated Vaccine by: Type (Price)
  • 6. Inactivated Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas Pharma (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. CSL Limited (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Emergent BioSolutions (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MedImmune (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Europe Inactivated Vaccine Sale, by Type, Application and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Europe Inactivated Vaccine (Value)
      • 7.2.1. Europe Inactivated Vaccine by: Type (Value)
        • 7.2.1.1. By End User
        • 7.2.1.2. Pediatrics
        • 7.2.1.3. Adults
        • 7.2.1.4. By Disease Indication
        • 7.2.1.5. Pneumococcal
        • 7.2.1.6. Influenza
        • 7.2.1.7. HPV
        • 7.2.1.8. Hepatitis
        • 7.2.1.9. Rotavirus
        • 7.2.1.10. DTP
        • 7.2.1.11. Polio
        • 7.2.1.12. MMR
      • 7.2.2. Europe Inactivated Vaccine by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Medical Center
      • 7.2.3. Europe Inactivated Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Europe Inactivated Vaccine (Volume)
      • 7.3.1. Europe Inactivated Vaccine by: Type (Volume)
        • 7.3.1.1. By End User
        • 7.3.1.2. Pediatrics
        • 7.3.1.3. Adults
        • 7.3.1.4. By Disease Indication
        • 7.3.1.5. Pneumococcal
        • 7.3.1.6. Influenza
        • 7.3.1.7. HPV
        • 7.3.1.8. Hepatitis
        • 7.3.1.9. Rotavirus
        • 7.3.1.10. DTP
        • 7.3.1.11. Polio
        • 7.3.1.12. MMR
      • 7.3.2. Europe Inactivated Vaccine by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Medical Center
      • 7.3.3. Europe Inactivated Vaccine Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Europe Inactivated Vaccine (Price)
      • 7.4.1. Europe Inactivated Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Inactivated Vaccine: by Type(USD Million)
  • Table 2. Inactivated Vaccine By End User , by Region USD Million (2018-2023)
  • Table 3. Inactivated Vaccine Pediatrics , by Region USD Million (2018-2023)
  • Table 4. Inactivated Vaccine Adults , by Region USD Million (2018-2023)
  • Table 5. Inactivated Vaccine By Disease Indication , by Region USD Million (2018-2023)
  • Table 6. Inactivated Vaccine Pneumococcal , by Region USD Million (2018-2023)
  • Table 7. Inactivated Vaccine Influenza , by Region USD Million (2018-2023)
  • Table 8. Inactivated Vaccine HPV , by Region USD Million (2018-2023)
  • Table 9. Inactivated Vaccine Hepatitis , by Region USD Million (2018-2023)
  • Table 10. Inactivated Vaccine Rotavirus , by Region USD Million (2018-2023)
  • Table 11. Inactivated Vaccine DTP , by Region USD Million (2018-2023)
  • Table 12. Inactivated Vaccine Polio , by Region USD Million (2018-2023)
  • Table 13. Inactivated Vaccine MMR , by Region USD Million (2018-2023)
  • Table 14. Inactivated Vaccine: by Application(USD Million)
  • Table 15. Inactivated Vaccine Hospital , by Region USD Million (2018-2023)
  • Table 16. Inactivated Vaccine Medical Center , by Region USD Million (2018-2023)
  • Table 17. South America Inactivated Vaccine, by Country USD Million (2018-2023)
  • Table 18. South America Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 19. South America Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 20. Brazil Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 21. Brazil Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 22. Argentina Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 23. Argentina Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 24. Rest of South America Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 26. Asia Pacific Inactivated Vaccine, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 28. Asia Pacific Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 29. China Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 30. China Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 31. Japan Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 32. Japan Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 33. India Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 34. India Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 35. South Korea Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 36. South Korea Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 37. Taiwan Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 38. Taiwan Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 39. Australia Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 40. Australia Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 41. Rest of Asia-Pacific Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 42. Rest of Asia-Pacific Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 43. Europe Inactivated Vaccine, by Country USD Million (2018-2023)
  • Table 44. Europe Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 45. Europe Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 46. Germany Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 47. Germany Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 48. France Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 49. France Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 50. Italy Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 51. Italy Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 52. United Kingdom Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 53. United Kingdom Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 54. Netherlands Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 55. Netherlands Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 56. Rest of Europe Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 57. Rest of Europe Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 58. MEA Inactivated Vaccine, by Country USD Million (2018-2023)
  • Table 59. MEA Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 60. MEA Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 61. Middle East Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 62. Middle East Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 63. Africa Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 64. Africa Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 65. North America Inactivated Vaccine, by Country USD Million (2018-2023)
  • Table 66. North America Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 67. North America Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 68. United States Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 69. United States Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 70. Canada Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 71. Canada Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 72. Mexico Inactivated Vaccine, by Type USD Million (2018-2023)
  • Table 73. Mexico Inactivated Vaccine, by Application USD Million (2018-2023)
  • Table 74. Inactivated Vaccine Sales: by Type(K Units)
  • Table 75. Inactivated Vaccine Sales By End User , by Region K Units (2018-2023)
  • Table 76. Inactivated Vaccine Sales Pediatrics , by Region K Units (2018-2023)
  • Table 77. Inactivated Vaccine Sales Adults , by Region K Units (2018-2023)
  • Table 78. Inactivated Vaccine Sales By Disease Indication , by Region K Units (2018-2023)
  • Table 79. Inactivated Vaccine Sales Pneumococcal , by Region K Units (2018-2023)
  • Table 80. Inactivated Vaccine Sales Influenza , by Region K Units (2018-2023)
  • Table 81. Inactivated Vaccine Sales HPV , by Region K Units (2018-2023)
  • Table 82. Inactivated Vaccine Sales Hepatitis , by Region K Units (2018-2023)
  • Table 83. Inactivated Vaccine Sales Rotavirus , by Region K Units (2018-2023)
  • Table 84. Inactivated Vaccine Sales DTP , by Region K Units (2018-2023)
  • Table 85. Inactivated Vaccine Sales Polio , by Region K Units (2018-2023)
  • Table 86. Inactivated Vaccine Sales MMR , by Region K Units (2018-2023)
  • Table 87. Inactivated Vaccine Sales: by Application(K Units)
  • Table 88. Inactivated Vaccine Sales Hospital , by Region K Units (2018-2023)
  • Table 89. Inactivated Vaccine Sales Medical Center , by Region K Units (2018-2023)
  • Table 90. South America Inactivated Vaccine Sales, by Country K Units (2018-2023)
  • Table 91. South America Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 92. South America Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 93. Brazil Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 94. Brazil Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 95. Argentina Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 96. Argentina Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 97. Rest of South America Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 98. Rest of South America Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 99. Asia Pacific Inactivated Vaccine Sales, by Country K Units (2018-2023)
  • Table 100. Asia Pacific Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 101. Asia Pacific Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 102. China Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 103. China Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 104. Japan Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 105. Japan Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 106. India Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 107. India Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 108. South Korea Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 109. South Korea Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 110. Taiwan Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 111. Taiwan Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 112. Australia Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 113. Australia Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 114. Rest of Asia-Pacific Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 115. Rest of Asia-Pacific Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 116. Europe Inactivated Vaccine Sales, by Country K Units (2018-2023)
  • Table 117. Europe Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 118. Europe Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 119. Germany Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 120. Germany Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 121. France Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 122. France Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 123. Italy Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 124. Italy Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 125. United Kingdom Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 126. United Kingdom Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 127. Netherlands Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 128. Netherlands Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 129. Rest of Europe Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 130. Rest of Europe Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 131. MEA Inactivated Vaccine Sales, by Country K Units (2018-2023)
  • Table 132. MEA Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 133. MEA Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 134. Middle East Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 135. Middle East Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 136. Africa Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 137. Africa Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 138. North America Inactivated Vaccine Sales, by Country K Units (2018-2023)
  • Table 139. North America Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 140. North America Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 141. United States Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 142. United States Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 143. Canada Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 144. Canada Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 145. Mexico Inactivated Vaccine Sales, by Type K Units (2018-2023)
  • Table 146. Mexico Inactivated Vaccine Sales, by Application K Units (2018-2023)
  • Table 147. Inactivated Vaccine: by Type(USD/Units)
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Inactivated Vaccine: by Type(USD Million)
  • Table 157. Inactivated Vaccine By End User , by Region USD Million (2025-2030)
  • Table 158. Inactivated Vaccine Pediatrics , by Region USD Million (2025-2030)
  • Table 159. Inactivated Vaccine Adults , by Region USD Million (2025-2030)
  • Table 160. Inactivated Vaccine By Disease Indication , by Region USD Million (2025-2030)
  • Table 161. Inactivated Vaccine Pneumococcal , by Region USD Million (2025-2030)
  • Table 162. Inactivated Vaccine Influenza , by Region USD Million (2025-2030)
  • Table 163. Inactivated Vaccine HPV , by Region USD Million (2025-2030)
  • Table 164. Inactivated Vaccine Hepatitis , by Region USD Million (2025-2030)
  • Table 165. Inactivated Vaccine Rotavirus , by Region USD Million (2025-2030)
  • Table 166. Inactivated Vaccine DTP , by Region USD Million (2025-2030)
  • Table 167. Inactivated Vaccine Polio , by Region USD Million (2025-2030)
  • Table 168. Inactivated Vaccine MMR , by Region USD Million (2025-2030)
  • Table 169. Inactivated Vaccine: by Application(USD Million)
  • Table 170. Inactivated Vaccine Hospital , by Region USD Million (2025-2030)
  • Table 171. Inactivated Vaccine Medical Center , by Region USD Million (2025-2030)
  • Table 172. South America Inactivated Vaccine, by Country USD Million (2025-2030)
  • Table 173. South America Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 174. South America Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 175. Brazil Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 176. Brazil Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 177. Argentina Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 178. Argentina Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 179. Rest of South America Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 180. Rest of South America Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 181. Asia Pacific Inactivated Vaccine, by Country USD Million (2025-2030)
  • Table 182. Asia Pacific Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 183. Asia Pacific Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 184. China Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 185. China Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 186. Japan Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 187. Japan Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 188. India Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 189. India Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 190. South Korea Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 191. South Korea Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 192. Taiwan Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 193. Taiwan Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 194. Australia Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 195. Australia Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 198. Europe Inactivated Vaccine, by Country USD Million (2025-2030)
  • Table 199. Europe Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 200. Europe Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 201. Germany Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 202. Germany Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 203. France Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 204. France Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 205. Italy Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 206. Italy Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 207. United Kingdom Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 208. United Kingdom Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 209. Netherlands Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 210. Netherlands Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 211. Rest of Europe Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 212. Rest of Europe Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 213. MEA Inactivated Vaccine, by Country USD Million (2025-2030)
  • Table 214. MEA Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 215. MEA Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 216. Middle East Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 217. Middle East Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 218. Africa Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 219. Africa Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 220. North America Inactivated Vaccine, by Country USD Million (2025-2030)
  • Table 221. North America Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 222. North America Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 223. United States Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 224. United States Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 225. Canada Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 226. Canada Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 227. Mexico Inactivated Vaccine, by Type USD Million (2025-2030)
  • Table 228. Mexico Inactivated Vaccine, by Application USD Million (2025-2030)
  • Table 229. Inactivated Vaccine Sales: by Type(K Units)
  • Table 230. Inactivated Vaccine Sales By End User , by Region K Units (2025-2030)
  • Table 231. Inactivated Vaccine Sales Pediatrics , by Region K Units (2025-2030)
  • Table 232. Inactivated Vaccine Sales Adults , by Region K Units (2025-2030)
  • Table 233. Inactivated Vaccine Sales By Disease Indication , by Region K Units (2025-2030)
  • Table 234. Inactivated Vaccine Sales Pneumococcal , by Region K Units (2025-2030)
  • Table 235. Inactivated Vaccine Sales Influenza , by Region K Units (2025-2030)
  • Table 236. Inactivated Vaccine Sales HPV , by Region K Units (2025-2030)
  • Table 237. Inactivated Vaccine Sales Hepatitis , by Region K Units (2025-2030)
  • Table 238. Inactivated Vaccine Sales Rotavirus , by Region K Units (2025-2030)
  • Table 239. Inactivated Vaccine Sales DTP , by Region K Units (2025-2030)
  • Table 240. Inactivated Vaccine Sales Polio , by Region K Units (2025-2030)
  • Table 241. Inactivated Vaccine Sales MMR , by Region K Units (2025-2030)
  • Table 242. Inactivated Vaccine Sales: by Application(K Units)
  • Table 243. Inactivated Vaccine Sales Hospital , by Region K Units (2025-2030)
  • Table 244. Inactivated Vaccine Sales Medical Center , by Region K Units (2025-2030)
  • Table 245. South America Inactivated Vaccine Sales, by Country K Units (2025-2030)
  • Table 246. South America Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 247. South America Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 248. Brazil Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 249. Brazil Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 250. Argentina Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 251. Argentina Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 252. Rest of South America Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 253. Rest of South America Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 254. Asia Pacific Inactivated Vaccine Sales, by Country K Units (2025-2030)
  • Table 255. Asia Pacific Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 256. Asia Pacific Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 257. China Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 258. China Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 259. Japan Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 260. Japan Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 261. India Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 262. India Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 263. South Korea Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 264. South Korea Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 265. Taiwan Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 266. Taiwan Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 267. Australia Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 268. Australia Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 269. Rest of Asia-Pacific Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 270. Rest of Asia-Pacific Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 271. Europe Inactivated Vaccine Sales, by Country K Units (2025-2030)
  • Table 272. Europe Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 273. Europe Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 274. Germany Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 275. Germany Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 276. France Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 277. France Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 278. Italy Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 279. Italy Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 280. United Kingdom Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 281. United Kingdom Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 282. Netherlands Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 283. Netherlands Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 284. Rest of Europe Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 285. Rest of Europe Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 286. MEA Inactivated Vaccine Sales, by Country K Units (2025-2030)
  • Table 287. MEA Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 288. MEA Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 289. Middle East Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 290. Middle East Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 291. Africa Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 292. Africa Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 293. North America Inactivated Vaccine Sales, by Country K Units (2025-2030)
  • Table 294. North America Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 295. North America Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 296. United States Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 297. United States Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 298. Canada Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 299. Canada Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 300. Mexico Inactivated Vaccine Sales, by Type K Units (2025-2030)
  • Table 301. Mexico Inactivated Vaccine Sales, by Application K Units (2025-2030)
  • Table 302. Inactivated Vaccine: by Type(USD/Units)
  • Table 303. Research Programs/Design for This Report
  • Table 304. Key Data Information from Secondary Sources
  • Table 305. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Europe Inactivated Vaccine: by Type USD Million (2018-2023)
  • Figure 5. Europe Inactivated Vaccine: by Application USD Million (2018-2023)
  • Figure 6. South America Inactivated Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Inactivated Vaccine Share (%), by Country
  • Figure 8. Europe Inactivated Vaccine Share (%), by Country
  • Figure 9. MEA Inactivated Vaccine Share (%), by Country
  • Figure 10. North America Inactivated Vaccine Share (%), by Country
  • Figure 11. Europe Inactivated Vaccine: by Type K Units (2018-2023)
  • Figure 12. Europe Inactivated Vaccine: by Application K Units (2018-2023)
  • Figure 13. South America Inactivated Vaccine Share (%), by Country
  • Figure 14. Asia Pacific Inactivated Vaccine Share (%), by Country
  • Figure 15. Europe Inactivated Vaccine Share (%), by Country
  • Figure 16. MEA Inactivated Vaccine Share (%), by Country
  • Figure 17. North America Inactivated Vaccine Share (%), by Country
  • Figure 18. Europe Inactivated Vaccine: by Type USD/Units (2018-2023)
  • Figure 19. Europe Inactivated Vaccine share by Players 2023 (%)
  • Figure 20. Europe Inactivated Vaccine share by Players (Top 3) 2023(%)
  • Figure 21. Europe Inactivated Vaccine share by Players (Top 5) 2023(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Astellas Pharma (Japan) Revenue: by Geography 2023
  • Figure 25. CSL Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 26. CSL Limited (Australia) Revenue: by Geography 2023
  • Figure 27. Emergent BioSolutions (United States) Revenue, Net Income and Gross profit
  • Figure 28. Emergent BioSolutions (United States) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 33. MedImmune (United States) Revenue, Net Income and Gross profit
  • Figure 34. MedImmune (United States) Revenue: by Geography 2023
  • Figure 35. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co (United States) Revenue: by Geography 2023
  • Figure 37. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer (United States) Revenue: by Geography 2023
  • Figure 39. Europe Inactivated Vaccine: by Type USD Million (2025-2030)
  • Figure 40. Europe Inactivated Vaccine: by Application USD Million (2025-2030)
  • Figure 41. South America Inactivated Vaccine Share (%), by Country
  • Figure 42. Asia Pacific Inactivated Vaccine Share (%), by Country
  • Figure 43. Europe Inactivated Vaccine Share (%), by Country
  • Figure 44. MEA Inactivated Vaccine Share (%), by Country
  • Figure 45. North America Inactivated Vaccine Share (%), by Country
  • Figure 46. Europe Inactivated Vaccine: by Type K Units (2025-2030)
  • Figure 47. Europe Inactivated Vaccine: by Application K Units (2025-2030)
  • Figure 48. South America Inactivated Vaccine Share (%), by Country
  • Figure 49. Asia Pacific Inactivated Vaccine Share (%), by Country
  • Figure 50. Europe Inactivated Vaccine Share (%), by Country
  • Figure 51. MEA Inactivated Vaccine Share (%), by Country
  • Figure 52. North America Inactivated Vaccine Share (%), by Country
  • Figure 53. Europe Inactivated Vaccine: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Astellas Pharma (Japan)
  • CSL Limited (Australia)
  • Emergent BioSolutions (United States)
  • GlaxoSmithKline (United Kingdom)
  • Johnson & Johnson (United States)
  • MedImmune (United States)
  • Merck & Co (United States)
  • Pfizer (United States)
Additional players considered in the study are as follows:
Sanofi Pasteur (France) , Serum Institute of India Pvt (India)
Select User Access Type

Key Highlights of Report


Mar 2024 205 Pages 94 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Inactivated Vaccine Market Quantitative research analysis
Global Inactivated Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Longer timeline for vaccine production
  • High cost associated with development of vaccine

Know More About Global Inactivated Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Pain Management Therapeutics Comprehensive Study by Type (Antidepressants, Anesthetics, NSAIDs, Opioids, Anti-Migraine Agents, Other), Application (Burn Pain, Cancer Pain, Dental/Facial Pain, Migrain...
$ 3750
Mobile Clinics Comprehensive Study by Type (Eye-wear, Mobile health, Connected medical devices, Mhealth apps), Application (Diabetes, Cardiovascular Disease, Respiratory Diseases, Neurological Diseas...
$ 3500
Dental Wax Comprehensive Study by Type (Mineral Wax, Animal Wax, Plant Wax, Synthetic Wax), Application (Hospitals, Dentist Clinics, Academic and Research Centers, Others) Players and Region - Global...
$ 3500
Marijuana Oil Comprehensive Study by Type (Organic, Inorganic), Application (Vape Cartirdges, Subligual Drops& Sprays, Topical Creams & Salves, Gummies & Edibles, Softgel Capsules, Others), End Use (...
$ 3450
IT-enabled Healthcare Comprehensive Study by Application (Hospitals , Clinics , Household , Others), Services (M-Health, Tele-health Services), Software (Ancillary Information Systems, Administrative...
$ 3450
Extraction Devices Comprehensive Study by Type (Solid Phase, Liquid Phase), End User (Healthcare Industries, Chemical Industries, Food Industries, Others) Players and Region - Global Market Outlook t...
$ 3500